Pfizer Inc. initiates Covid-19 vaccine shipment trial
The company has selected Texas, New Mexico, Tennessee, and Rhode Island for the pilot program
avatar
Staff or Guest writer for The Dog of Wall Street.
2020-11-17 14:30

Pfizer Inc. (PFE) has commenced a pilot delivery program for its Covid-19 vaccine candidate in the four states of America, as the pharmaceutical giant looks to address the possible supply challenges it may face due to the ultra-cold storage required for its vaccine. 

The New York-based drug maker’s vaccine needs to be kept at -70°C or -94°F for both storage and during shipment. This is well below the storage temperature of 2-8°C needed by usual vaccines. 

Pfizer said in a statement “we are hopeful that results from this vaccine delivery pilot will serve as the model for other U.S. states and international governments, as they prepare to implement effective COVID-19 vaccine programs.”

The company has selected Texas, New Mexico, Tennessee, and Rhode Island for the pilot program due to their differences such as overall size and diversity of populations, as well as wide-ranging rural and urban settings. 

The pilot program is just for the testing purpose and does not mean that the aforesaid states will be given any kind of priority over other states during the actual distribution process, according to the company. 

Pfizer has commenced its pilot program just days after reporting its Covid-19 vaccine is more than 90 percent effective in preventing the virus. The announcement was based on the initial results from its late-stage mass trials. The company expects to have more data from the trial by the third week of this month, after which it plans to apply for emergency authorization of its vaccine. 

Pfizer has already inked a $1.95 billion deal with the United States government for supplying 100 million doses of the vaccine. The government has been given an option to buy an additional 500 million doses, if needed. 

Pfizer Inc. shares have been trading lower for the second straight day after Moderna announced that its experimental vaccine achieved more than 94 percent efficacy in preventing the coronavirus. Moderna results are also based on the interim data from its Phase-III trial.


Disclaimer: I have no positions in any of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article. All information should be independently verified and should not be relied upon for purposes of transacting securities or other investments. See terms for more info.

Published On
2020-11-17 14:30

avatar
About the Author
Staff or Guest writer for The Dog of Wall Street.

PFE


Better Investment: Pfizer or Moderna
This week I take a look at two stalwarts in the pharmaceutical industry, and the effect they have had on investors in the race for a COVID-19 vaccine.
By Mike Sakuraba | 1 month ago

AstraZeneca confuses investors after reporting two different efficacy rates achieved by its Covid-19 vaccine
AstraZeneca will sell its vaccine to governments at significantly lower prices as compared to Pfizer and Moderna.
By Staff | 1 year ago

Moderna Inc. (MRNA) says its Covid-19 vaccine more than 94 percent effective in Phase-III trials
Pfizer shares fell nearly 3 percent in the pre-market trading Monday following Moderna’s announcement.
By Staff | 1 year ago

Pfizer has a potential vaccine. Now what?
Industries like entertainment, travel and hospitality, airlines, cruise ships, and casinos, were just a few of the sectors that reacted positively to the news.
By Mike Sakuraba | 1 year ago
PFE

Pfizer Inc. (PFE) shares hit new 52-week high after positive results of Covid-19 vaccine
Pfizer says its experimental coronavirus vaccine more than 90 percent effective in trials
By Staff | 1 year ago

The COVID-19 vaccine market will not be a winner-takes-all
The US government has selected three vaccine candidates to fund their Phase 3 trials through Operation Warp Speed.
By Alcides | 1 year ago